These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 11248523

  • 41. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
    Flamm RK, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578
    [Abstract] [Full Text] [Related]

  • 42. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS, Mendes RE, Farrell DJ, Flamm RK, Jones RN.
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [Abstract] [Full Text] [Related]

  • 43. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ, Toleman M, Walsh TR, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [Abstract] [Full Text] [Related]

  • 44. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
    Sader HS, Castanheira M, Mendes RE, Flamm RK, Jones RN.
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
    [Abstract] [Full Text] [Related]

  • 45. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns.
    Sader HS, Jones RN, Silva JB, SENTRY Participants Group (Latin America).
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):281-8. PubMed ID: 12493176
    [Abstract] [Full Text] [Related]

  • 48. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [Abstract] [Full Text] [Related]

  • 49. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [Abstract] [Full Text] [Related]

  • 50. Microbiology and antibiotic susceptibility of organisms in bile cultures from patients with and without cholangitis at an Asian academic medical center.
    Salvador VB, Lozada MC, Consunji RJ.
    Surg Infect (Larchmt); 2011 Apr; 12(2):105-11. PubMed ID: 21348769
    [Abstract] [Full Text] [Related]

  • 51. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
    Jones RN, Stilwell MG, Rhomberg PR, Sader HS.
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):331-4. PubMed ID: 19822273
    [Abstract] [Full Text] [Related]

  • 52. Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program.
    Deshpande LM, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):231-6. PubMed ID: 15313526
    [Abstract] [Full Text] [Related]

  • 53. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
    Biedenbach DJ, Moet GJ, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279
    [Abstract] [Full Text] [Related]

  • 54. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS, Huband MD, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [Abstract] [Full Text] [Related]

  • 55. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1993)].
    Ikemoto H, Watanabe K, Mori T, Igari J, Oguri T, Kobayashi K, Satou K, Matsumiya H, Saito A, Terai T, Tanno Y, Nishioka K, Arakawa M, Wada K, Okada M, Ozaki K, Aoki N, Kitamura N, Sekine O, Suzuki Y, Tanimoto H, Nakata K, Nakamori Y, Nakatani T, Kusano N.
    Jpn J Antibiot; 1996 Feb; 49(2):107-43. PubMed ID: 8721076
    [Abstract] [Full Text] [Related]

  • 56. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
    Xu Y, Chen M, Biedenbach DJ, Deshpande LM, Jones RN.
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
    [Abstract] [Full Text] [Related]

  • 57. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ.
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [Abstract] [Full Text] [Related]

  • 58. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H, Watanabe K, Mori T, Igari J, Oguri T, Kobayashi K, Satou K, Matsumiya H, Saito A, Terai T, Tanno Y, Nishioka K, Arakawa M, Wada K, Okada M, Ozaki K, Aoki N, Kitamura N, Sekine O, Suzuki Y, Matsuda M, Tanimoto H, Nakata K, Nakamori Y, Kusano N.
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [Abstract] [Full Text] [Related]

  • 59. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
    Jones RN, Salazar JC, Pfaller MA, Doern GV.
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
    [Abstract] [Full Text] [Related]

  • 60. Surveillance of the Activity of Aminoglycosides and Fluoroquinolones Against Ophthalmic Pathogens from Europe in 2010-2011.
    Sanfilippo CM, Morrissey I, Janes R, Morris TW.
    Curr Eye Res; 2016 May; 41(5):581-9. PubMed ID: 26200173
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.